Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.56 |
| ▸ | TP53 | P04637 | 9/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31585998 | 1.00 | MAPT (0.56) | MAPTTP53LMNAMEN1KMT2A | |
| SCHEMBL27995397 | 0.93 | MAPT (0.50) | MAPTTP53LMNAMEN1KMT2A | |
| SCHEMBL26159157 | 0.90 | MAPT (0.51) | MAPTTP53LMNAMEN1KMT2A | |
| SCHEMBL16628386 | 0.85 | MAPT (0.57) | MAPTTP53LMNAPOLBCYP11B1 | |
| SCHEMBL2704794 | 0.84 | KMT2A (0.56) | MAPTTP53MEN1KMT2ACYP11B1 | |
| SCHEMBL4726759 | 0.82 | HTR6 (0.50) | MAPTTP53LMNAMEN1KMT2A | |
| SCHEMBL1495922 | 0.82 | KCNN4 (0.64) | MAPTTP53MEN1KMT2ACYP11B1 | |
| SCHEMBL7383036 | 0.80 | CYP11B1 (0.49) | MAPTTP53LMNAMEN1KMT2A | |
| SCHEMBL31585745 | 0.80 | MAPT (0.48) | MAPTTP53LMNAMEN1KMT2A | |
| SCHEMBL20601668 | 0.80 | MAPT (0.48) | MAPTTP53LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4056557-B1 | BENZAZEPINE DERIVATIVES USEFUL AS MEDICAMENTS | OTSUKA PHARMA CO LTD (JP) | 2023-11-22 | — | — | EP | disclosed |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-11673878-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-10889570-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| EP-3645513-A1 | BENZAZEPINE DERIVATIVES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2020-05-06 | — | — | EP | disclosed |
| CN-110891939-A | Benzazepine derivatives | 大塚制药株式会社 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019004421-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | WO | disclosed |
| US-9024015-B2 | Process for preparing tolvaptan intermediates | HETERO RESEARCH FOUNDATION (IN) | 2015-05-05 | — | — | US | disclosed |
| US-8273735-B2 | Process for preparing benzazepine compounds or salts thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120226034-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-06 | — | — | US | disclosed |
| WO-2012046244-A1 | PROCESS FOR PREPARING TOLVAPTAN INTERMEDIATES | HETERO RESEARCH FOUNDATION (IN) | 2012-04-12 | — | — | WO | disclosed |
| EP-2251319-B1 | Process for preparing derivatives of benzoic acid | OTSUKA PHARMA CO LTD (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-1919874-B1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMA CO LTD (JP) | 2011-01-26 | — | — | EP | disclosed |
| EP-2261215-A1 | Process for preparing benzazepine compounds or salts thereof | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2251319-A2 | Process for preparing derivatives of benzoic acid | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20090306369-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1919874-A2 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | Otsuka Pharmaceutical Company, Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026971-A2 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306369-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | AVPR2, AVPR1B, AVPR1A | MAPT 3415/4885TP53 4593/4885LMNA 925/4885 |
| US-20120226034-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | AVPR2, AVPR1B, AVPR1A | MAPT 3415/4885TP53 4593/4885LMNA 925/4885 |
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | MAPT 3910/4885TP53 3007/4885LMNA 1192/4885 |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | MAPT 3910/4885TP53 3007/4885LMNA 1192/4885 |
| US-11673878-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | MAPT 3910/4885TP53 3007/4885LMNA 1192/4885 |
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | MAPT 3362/4885TP53 3086/4885LMNA 782/4885 |
| US-10889570-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | MAPT 3910/4885TP53 3007/4885LMNA 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.